ESMO Media Releases

The platform in Europe devoted entirely to the development and use of the immunotherapies against cancer, will take place from 11-14 December in Geneva, Switzerland with thousand participants from all over the world.

SINGAPORE- The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomised phase III study to be reported at the ESMO Asia Congress 2019.

SINGAPORE – Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) compared to standard of care, showed results from a phase 3 study to be reported at the ESMO Asia 2019 Congress.

Over 3,500 medical professionals are convening for the three-day scientific and educational congress to drive progress and contribute to shaping the oncology roadmap in the Asia-Pacific region

The European Society for Medical Oncology has selected Prof. Thomas Gajewski to receive the 2019 ESMO Award for Immuno-Oncology. 

New data have shown for the first time that targeted therapy can improve the outcome of patients diagnosed with advanced cholangiocarcinoma.

Targeting faulty DNA repair mechanisms in advanced castration resistant prostate cancer can slow progression and potentially improve survival, paving the way for a new approach to treatment of the most common form of cancer in men.

Patients with metastatic urothelial cancer have longer progression free survival when treated with first-line immunotherapy and chemotherapy instead of chemotherapy alone, according to late breaking results of the IMvigor130 trial presented at the ESMO Congress 2019 in Barcelona, Spain.

Patients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may provide important clues to novel treatment for the thousands of new cases each year.

A growing number of patients with advanced lung cancer could soon be offered a blood test to help to decide the best treatment for them instead of having to get a tumour sample for analysis.

New data from two studies reported at the ESMO Congress 2019 have shown that treatment with a CDK4/6 inhibitor plus fulvestrant improves overall survival in women with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer

Immune therapy added to chemotherapy improves pathological complete response in patients with early triple negative breast cancer, according to late breaking results from the KEYNOTE-522 trial presented at the ESMO Congress 2019 in Barcelona, Spain.